Kargbo Robert B
Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
ACS Med Chem Lett. 2024 Oct 15;15(11):1812-1814. doi: 10.1021/acsmedchemlett.4c00490. eCollection 2024 Nov 14.
Recent advancements in the therapeutic use of psychedelic compounds, particularly 5-MeO-DMT and DMT, have demonstrated significant potential in treating various mental health disorders. This Patent Highlight evaluates findings from multiple recent patents that explore novel applications of these compounds, including their use in severe psychiatric conditions such as depression, anxiety, and trauma-related disorders. The patents reveal innovative strategies, such as combining 5-MeO-DMT with mood preparation agents to enhance safety and efficacy, developing DMT prodrugs for improved pharmacokinetics, and targeting specific populations like breastfeeding mothers with tailored psychedelic therapies. These advancements offer new hope for patients with treatment-resistant mental disorders, highlighting the evolving role of psychedelics in mental health care.
迷幻化合物，特别是5-甲氧基二甲基色胺（5-MeO-DMT）和二甲基色胺（DMT）在治疗用途上的最新进展，已显示出在治疗各种心理健康障碍方面的巨大潜力。本专利亮点评估了多项近期专利的研究结果，这些专利探索了这些化合物的新应用，包括它们在严重精神疾病如抑郁症、焦虑症和创伤相关障碍中的应用。这些专利揭示了创新策略，如将5-MeO-DMT与情绪准备剂联合使用以提高安全性和疗效，开发用于改善药代动力学的DMT前药，以及针对特定人群如哺乳期母亲采用量身定制的迷幻疗法。这些进展为患有难治性精神障碍的患者带来了新希望，突出了迷幻剂在精神卫生保健中不断演变的作用。
